# NEUROCRINE BIOSCIENCES, INC. (NBIX) FY2026 Q2 P&L / Income Statement

- Company: NEUROCRINE BIOSCIENCES, INC. (NBIX)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-31, accession number 0000914475-26-000037
- Page: https://plicit.ai/financials/nbix/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/nbix-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 959,000,000 US dollars
- **Cost of revenue (calculated)**: 23,200,000 US dollars
- **Gross profit (calculated)**: 935,800,000 US dollars
- **Operating expenses (calculated)**: 784,300,000 US dollars
- **Operating income**: 151,500,000 US dollars
- **Total other income, net**: 10,700,000 US dollars
- **Income before provision for income taxes**: 162,200,000 US dollars
- **Provision for income taxes**: 17,800,000 US dollars
- **Net income**: 144,400,000 US dollars
- **Net product sales**: 954,300,000 US dollars
- **Collaboration revenues**: 4,700,000 US dollars
- **Cost of revenues, excluding amortization of acquired intangible assets**: 23,200,000 US dollars
- **Research and development**: 326,700,000 US dollars
- **Acquired in-process research and development**: 1,500,000 US dollars
- **Selling, general, and administrative**: 439,700,000 US dollars
- **Amortization of acquired intangible assets**: 16,400,000 US dollars
- **Gain on sale of business, net of transaction costs**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details

- Page: https://plicit.ai/financials/nbix/fy2026-q2-income-statement/views/view-030853dd19e7de1270a9
- Chart image: https://plicit.ai/charts/nbix-fy2026-q2-income-statement-view-view-030853dd19e7de1270a9-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Segments by Research and Development Arrangement, Contract to Perform for Others, Type. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 959,000,000 US dollars
- **Cost of revenue (calculated)**: 23,200,000 US dollars
- **Gross profit (calculated)**: 935,800,000 US dollars
- **Operating expenses (calculated)**: 784,300,000 US dollars
- **Operating income**: 151,500,000 US dollars
- **Total other income, net**: 10,700,000 US dollars
- **Income before provision for income taxes**: 162,200,000 US dollars
- **Provision for income taxes**: 17,800,000 US dollars
- **Net income**: 144,400,000 US dollars
- **Reportable Segment - CRENESSITY net product sales**: 183,500,000 US dollars
- **Reportable Segment - INGREZZA net product sales**: 716,500,000 US dollars
- **Reportable Segment - Other revenues**: 4,700,000 US dollars
- **Reportable Segment - VYKAT XR net product sales**: 54,300,000 US dollars
- **Cost of revenues, excluding amortization of acquired intangible assets**: 23,200,000 US dollars
- **Research and development**: 326,700,000 US dollars
- **Acquired in-process research and development**: 1,500,000 US dollars
- **Selling, general, and administrative**: 439,700,000 US dollars
- **Amortization of acquired intangible assets**: 16,400,000 US dollars
- **Gain on sale of business, net of transaction costs**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.